dc.contributor.author | El, Cheikh, J. | |
dc.contributor.author | Ngoya, M. | |
dc.contributor.author | Galimard, J.-E. | |
dc.contributor.author | Reményi, P. | |
dc.contributor.author | Kulagin, A. | |
dc.contributor.author | Aljurf, M. | |
dc.contributor.author | Mousavi, A. | |
dc.date.accessioned | 2025-01-12T18:55:07Z | |
dc.date.available | 2025-01-12T18:55:07Z | |
dc.date.issued | 2024 | |
dc.identifier.issn | 0003-469X | |
dc.identifier.uri | https://doi.org/10.1038/s41409-024-02300-8 | |
dc.identifier.uri | http://hdl.handle.net/11446/5059 | |
dc.description.abstract | T-cell acute lymphoblastic leukemia (T-ALL) predominantly affects individuals in late childhood and young adulthood. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative modality particularly in the setting of poor risk genetics and/or persistent minimal residual disease. Limited studies have directly explored the impact of patient- and transplant-related factors on post-transplant outcomes in T-ALL. Using a large dataset from the European Society for Blood and Marrow Transplantation registry, we identified 1907 adult T-ALL patients (70% male) who underwent their first allo-HSCT in first complete remission (CR1) from matched sibling donors (MSD; 45%), unrelated donors (UD; 43%) or haploidentical donors (12%) between 2010 and 2021. The median age at transplant was 33.4 years (18.1–75). The median follow up was 2.9 years. Most patients underwent total body irradiation (TBI)-based myeloablative conditioning (69%). The 2-year overall survival (OS) was 69.4%, and leukemia -free survival (LFS) was 62.1%. In multivariate analysis, advanced age at transplant negatively affected LFS (for each 10-year increment, HR = 1.11, p = 0.004), GVHD-free, relapse-free survival (GRFS) (HR = 1.06, p = 0.04), OS (HR = 1.12, p = 0.002), and non-relapse mortality (NRM) (HR = 1.23, p < 0.001). More recent years of allo-HSCT were associated with improved GFRS (For each 3-year increment, HR = 0.89, p < 0.001), OS (HR = 0.9, p = 0.02), and decreased NRM (HR = 0.82, p = 0.008). TBI improved LFS. (HR = 0.79, p = 0.02), GRFS (HR = 0.83, p = 0.04), and relapse incidence (RI) (HR = 0.65, p < 0.001). Female-to-male transplant negatively affected GRFS (HR = 1.21, p = 0.02) and OS (HR = 1.23, p = 0.048). In vivo T-cell depletion significantly improved GFRS (HR = 0.74, p < 0.001). This large study identified prognostic factors, such as age at transplant conditioning regimen, in influencing post-transplant in adult T-ALL patients undergoing allo-HSCT. Importantly, a significant improvement over time was noted. These findings hold great promise for new adapted treatment strategies and can serve as a benchmark for future studies in that setting. © The Author(s), under exclusive licence to Springer Nature Limited 2024. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer Nature | en_US |
dc.relation.ispartof | Bone Marrow Transplantation | en_US |
dc.identifier.doi | 10.1038/s41409-024-02300-8 | |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Adolescent | en_US |
dc.subject | Adult | en_US |
dc.subject | Aged | en_US |
dc.subject | Female | en_US |
dc.subject | Hematopoietic Stem Cell Transplantation | en_US |
dc.subject | Humans | en_US |
dc.subject | Male | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | en_US |
dc.subject | Prognosis | en_US |
dc.subject | Registries | en_US |
dc.subject | Survival Rate | en_US |
dc.subject | Transplantation Conditioning | en_US |
dc.subject | Young Adult | en_US |
dc.subject | alemtuzumab | en_US |
dc.subject | cyclophosphamide | en_US |
dc.subject | cyclosporine | en_US |
dc.subject | globulin | en_US |
dc.subject | methotrexate | en_US |
dc.subject | mycophenolate mofetil | en_US |
dc.subject | acute leukemia | en_US |
dc.subject | adult | en_US |
dc.subject | aged | en_US |
dc.subject | allogeneic hematopoietic stem cell transplantation | en_US |
dc.subject | Article | en_US |
dc.subject | bone marrow | en_US |
dc.subject | chronic graft versus host disease | en_US |
dc.subject | Cytomegalovirus | en_US |
dc.subject | disease free survival | en_US |
dc.subject | female | en_US |
dc.subject | follow up | en_US |
dc.subject | graft versus host reaction | en_US |
dc.subject | hematopoietic stem cell transplantation | en_US |
dc.subject | human | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | mortality | en_US |
dc.subject | outcome assessment | en_US |
dc.subject | overall survival | en_US |
dc.subject | prognosis | en_US |
dc.subject | recurrence free survival | en_US |
dc.subject | T cell acute lymphoblastic leukemia | en_US |
dc.subject | adolescent | en_US |
dc.subject | hematopoietic stem cell transplantation | en_US |
dc.subject | middle aged | en_US |
dc.subject | procedures | en_US |
dc.subject | prognosis | en_US |
dc.subject | register | en_US |
dc.subject | survival rate | en_US |
dc.subject | T cell acute lymphoblastic leukemia | en_US |
dc.subject | therapy | en_US |
dc.subject | transplantation conditioning | en_US |
dc.subject | young adult | en_US |
dc.title | Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working party | en_US |
dc.type | article | en_US |
dc.department | DBÜ | en_US |
dc.identifier.issue | 9 | en_US |
dc.identifier.volume | 59 | en_US |
dc.identifier.startpage | 1239 | en_US |
dc.identifier.endpage | 1246 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | El Cheikh J., Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Ngoya M., EBMT Statistical Unit, Saint Antoine Hospital, Sorbonne University, Paris, France; Galimard J.-E., EBMT Statistical Unit, Saint Antoine Hospital, Sorbonne University, Paris, France; Reményi P., Dél-pesti Centrumkórház –Országos Hematológiai és Infektológiai Intézet, Dept. Haematology and Stem Cell Transplant, Albert—Budapest, Budapest, Hungary; Kulagin A., RM Gorbacheva Research Institute, Pavlov University, Saint Petersburg, Russian Federation; Aljurf M., King Faisal Specialist Hospital & amp; Research Centre, Oncology (Section of Adult Haematolgy/BMT)—Riyadh, Riyadh, Saudi Arabia; Mousavi A., Shariati Hospital, Hematology-Oncology and BMT Research—Teheran, Tehran, Iran; Wu D., First Affiliated Hospital of Soochow University, Department of Hematology—Suzhou, Suzhou, China; Ozcelik T., Demiroglu Bilim University Istanbul Florence Nightingale Hospital, Hematopoietic SCT, Unit—Istanbul, İstanbul, Turkey; Salmenniemi U., HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit—Helsinki, Helsinki, Finland; Castilla-Llorente C., Gustave Roussy Cancer Campus, BMT Service, De | en_US |
dc.identifier.pmid | 38834689 | en_US |
dc.identifier.scopus | 2-s2.0-85195171247 | en_US |
dc.authorscopusid | 57190088309 | |
dc.authorscopusid | 57226109363 | |
dc.authorscopusid | 57189886743 | |
dc.authorscopusid | 6603458868 | |
dc.authorscopusid | 57788890000 | |
dc.authorscopusid | 55863021500 | |
dc.authorscopusid | 57222718733 | |